FDA: Pfizer vaccine 90.7% effective in kids aged 5-11

Home page Health
12 Punto 14 Punto 16 Punto 18 Punto

The United States Food and Drug Administration (FDA) revealed on Friday its latest study found Pfizer Inc. and BioNTech SE's vaccine against COVID-19 is 90.7% effective against the disease in children aged between five and 11. reports that the trials were conducted in 2,268 individuals divided into two groups. Those that received both doses of the jab developed an immunity of 90.7% in comparison to those that got a placebo.

Pfizer asked for the FDA's approval for the use of its treatment in kids earlier this month.

2021.10.22 / 20:31
See also

Pfizer shows long-term efficacy in adolescents

More time on screens means more soda, sports drinks

Pfizer: Our new COVID pill reduces risk of death by 89%

Long-term complications of the corona have been revealed

Sinovac again reduced the time of the third dose

WHO calls for action to protect health and care workers

Warning from scientists about a new mutation

AstraZeneca antibody shot prevents severe Covid - trial

WHO backs rollout of malaria vaccine for African children

UNICEF: 1 in 7 young people suffer from mental disorders

Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla